Ongoing and unsaid on oxaliplatin: The hope

British Journal of Cancer

Volumn 77, Issue SUPPL. 4, 1998, Pages 8-11

  Cvitkovic, E ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Diaminocyclohexane platinum; Favourable safety profile; Mismatch repair system; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; TOPOTECAN;

BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DNA ADDUCT; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031810003     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.429     Document Type: Article

References (24)

1. Alvarez M, Ortuzar W, Rixe O, Parker R, Reed E and Fojo T (1994) Cross resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Am Assoc Cancer Res 35: 439, 2616
2. André T, Bensmaine MA, Louvet C, Lucas V, Beerblock K, Desseigne F, Francois E, Merrouche Y, Bouche O, Morvan F, Carola E and de Gramont A (1997) Addition of oxaliplatin to the same leucovorin and 5-fluorouracil bimonthly regimen after progression in patients with metastatic colorectal cancer: preliminary report. Am Soc Clin Oncol 16: 270a, 958
3. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF and Nasca S (1997) Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Am Soc Clin Oncol 16: 229a, 804
4. Brown R, Hirst GL, Gallagher WM, McIlvrath AJ, Margison GP, van der Zee AG and Anthony DA (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45-52
5. Chollet P, Bensmaïne MA, Brienza S, Deloche C, Curé H, Caillet H and Cvitkovic E (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1065-1070
6. Cvitkovic E, Wasserman E, Goldwasser F, Rougier P, Tigand JM, Mahjoubi M, Magherini E and Misset JL (1997) Preliminary report on an oxaliplatin/CPT-11 phase I trial in gastrointestinal malignancies: an active combination. Am Soc Clin Oncol 16: 229a, 806
7. Dièras V et al (1998) Oxaliplatin phase II study in platinum pretreated advanced ovarian carcinoma: preliminary results. Am Soc Clin Oncol (submitted)
8. Extra JM, Espie M, Calvo F, Ferme C, Mignot L and Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303
9. Faivre S, Bourdon O, Bensmaine MA, Extra JM, Gautier H, Cvitkovic E and Marty M (1997) Paclitaxel/oxaliplatin association in pretreated recurrent ovarian carcinoma patients. Am Soc Clin Oncol 16: 369a, 1315
10. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL and Howell SB (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841-1845
11. Garufi C, Nistico C, Brienza S, Pace R, Aschelter AM, Rotarski M, Galla DAP and Terzoli E (1997) Oxaliplatin activity in anthracycline resistant metastatic breast cancer patients. Am Soc Clin Oncol 16: 170a, 595
12. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176
13. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, Letourneau Y, Chollet P, Llory JF, Coudert B, Bertheault-Cvitkovic F, Adam R, Le Bail N, Misset JL, Bayssas M and Lévi F for The International Organisation for Cancer Chemotherapy, FMSIT Hôpital P Brousse, Villejuif, and Debiopharm SA (1997) Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with colorectal cancer. Am Soc Clin Oncol 16: 229a, 805
14. de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219
15. Mathé G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, de Vassals F, Chenu E et al (1989) Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43: 237-250
16. Missel JL, Kidani Y, Gastiaburu J, Jasmin C, Lei F and Boughattas G (1991) Oxaliplatinum (L-OHP): experimental and clinical studies. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Howell SB. (ed.), Plenum Press: New York, p. 374
17. Misset JL, Chollet Ph, Vennin Ph, Laplaige Ph, Lucas V, Frobert JL, Castera D, Fabbro M, Langlais D, Dupont-Andre G, Otero G and Fandi A (1997) Multicentric phase II-III trial of oxaliplatin versus cisplatin both in association with cyclophosphamide in the treatment of advanced ovarian cancer: toxicity and efficacy results. Am Soc Clin Oncol 16: 354a, 1266
18. Monnet I et al (1998) Preliminary report on oxaliplatin/navelbine phase I-II trial in patients with advanced non-small cell lung cancer (NSCLC): an active combination. Eur J Cancer (in press)
19. Ortuzar W, Paull K, Rixe O and Fojo T (1994) Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistance sublines. Proc Am Assoc Cancer Res 35: 332
20. Raymond E et al (1997) Activity of oxaliplatin against human tumor colony forming units. Clin Cancer Res (in press)
21. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K and Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865.
22. Rotarski M et al (1993) Oxaliplatin (L-OHP), a new platinum analog, active in refractory/relapsed intermediate- and low-grade non-Hodgkin's lymphoma (NHL): a phase I-II study. Am Soc Clin Oncol 12: 1273a
23. Soulié P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M, Jasmin C, Musset M, Misset JL and Cvitkovic E (1997) Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33: 1400-1406
24. Zeghari-Squalli N et al (1997) Mechanism of the in vitro synergism between SN38 and oxaliplatin. Am Soc Clin Oncol 16: 20a, 906